Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "Sorbitol dehydrogenase 2, pseudogene" (abbreviated SORD2P) is a pseudogene—a segment of DNA that resembles a gene but is typically nonfunctional and does not encode a functional protein or RNA product[5]. Unlike functional proteins such as sorbitol dehydrogenase, which plays a critical role in carbohydrate metabolism by converting sorbitol to fructose, SORD2P does not have known enzymatic function, physiological activity, or implication as a drug target[1][5][3]. There are no known molecular functions, associated disease roles, or drug interactions for SORD2P. This entry is not considered a therapeutic target, and its naming may lead to confusion with the active sorbitol dehydrogenase (gene symbol SORD), which is a distinct, functional enzyme[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sorbitol dehydrogenase 2, pseudogene (SORD2P).